Safety and outcomes of 177 Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia.

Enmoore LinTina ChenAlana LittleLaura HollidayPaul RoachPatrick ButlerErika HoskingElizabeth BaileyBarry ElisonDavid Currow

Published in: Internal medicine journal (2020)

177 Lu-DOTATATE is a promising treatment for advanced NET. Superior survival in patients who met selection criteria emphasise the importance of protocol adherence.

Keyphrases

pet ct
neuroendocrine tumors
randomized controlled trial
tyrosine kinase
adipose tissue
free survival
replacement therapy